Oneg Hakarmel

Company Overview

Snapshot

Founded in January 2002 by Prof. Noam Gavriely, Oneg Hakarmel operates with 11–50 employees. The company focuses on developing medical devices for various surgical and emergency applications. In November 2018, Oneg Hakarmel launched HemaShock, an emergency auto-transfusion tourniquet designed to improve survival rates in cases of severe shock or cardiac arrest.

Business overview

Oneg Hakarmel manufactures and sells products for orthopedic surgery, vascular surgery, and emergency medicine. Its core technology involves patent-protected, single-use devices that efficiently displace blood from limbs and prevent its re-entry, creating a bloodless surgical field. The company's HemaClear line of sterile surgical products is widely used for this purpose, while the EED product line is designed for emergency medicine to auto-transfuse a patient's own blood during severe shock or cardiopulmonary resuscitation. Oneg Hakarmel's products are FDA listed and CE marked, serving the healthcare and life sciences sectors, particularly providers.

Strategic signal

In January 2019, Oneg Hakarmel's HemaShock device garnered significant attention, highlighted by articles in FMIBlog and The Jerusalem Post. This device, launched in November 2018, is an emergency auto-transfusion tourniquet designed to rapidly move blood from limbs into central circulation during severe shock or cardiac arrest. This indicates a strategic focus on critical care solutions and positions the company as an innovator in emergency medical devices with the potential to significantly impact patient outcomes.

Company Intelligence Q&A

What is Oneg Hakarmel's primary focus?

Oneg Hakarmel manufactures and sells products for orthopedic surgery, vascular surgery, and emergency medicine, leveraging patent-protected technology for blood displacement and re-entry prevention in limbs.

When was Oneg Hakarmel founded?

Oneg Hakarmel was founded in January 2002.

What is the HemaShock device?

The HemaShock is an emergency auto-transfusion tourniquet launched by Oneg Hakarmel in November 2018. It is designed to quickly move blood from the limbs into central circulation for patients experiencing very low systolic blood pressure due to hemodynamic shock or cardiac arrest.

What is the HemaClear product line?

The HemaClear line consists of sterile surgical products from Oneg Hakarmel, widely used to create a bloodless surgical field during operations by displacing blood from the limbs and blocking its re-entry.

Does Oneg Hakarmel have international market presence?

Yes, in June 2013, OHK Medical Devices (Oneg Hakarmel) partnered with Mitsubishi Corp. to launch HemaClear® in Japan, indicating an international market presence.